Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor
- PMID: 18063935
Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor
Abstract
The expression of vascular endothelial growth factor receptor 1(VEGFR-1) in human multiple myeloma KM3 cells in vitro, effects of valproic acid (VPA), as a histone deacetylase inhibitor, on cell proliferation and apoptosis and the underlying molecular mechanism were investigated. The effects of VPA on the growth of KM3 cells were studied by MTT assay. The apoptosis rate was determined with flow cytometry. The mRNA level of VEGFR was determined by RT-PCR; and immunocytochemistry was used to detect the protein level of ac-H4 and VEGFR. VPA inhibited proliferation of KM3 cells in a time- and dose-dependent manner. Treatment with VPA (4, 2, 1 and 0.5 mmol/L) for 48h, the apoptosis rates of KM3 cells were (13.27+/-3.54)%, (22.13+/-1.20)%, (24.41+/-2.23)% and(40.62+/-4.28)% respectively. The expression of VEGFR-1 in KM3 cells were decreased in VPA-treated group by the immunochemistry and RT-PCR, whereas the acetylated histone H4(ac-H4) accumulated. It suggested VPA could decrease the expression of VEGFR-1 in KM3 cells, and it might play an important role in regulating the proliferation and apoptosis of multiple myeloma cell line KM3 cells. These results provide the framework for clinical trials.
Similar articles
-
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.Haematologica. 2006 Feb;91(2):248-51. Haematologica. 2006. PMID: 16461312
-
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.Br J Haematol. 2008 Nov;143(4):520-31. doi: 10.1111/j.1365-2141.2008.07387.x. Br J Haematol. 2008. PMID: 18986388
-
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.Int J Urol. 2007 Sep;14(9):838-45. doi: 10.1111/j.1442-2042.2007.01823.x. Int J Urol. 2007. PMID: 17760752
-
Valproic acid for the treatment of myeloid malignancies.Cancer. 2007 Sep 1;110(5):943-54. doi: 10.1002/cncr.22891. Cancer. 2007. PMID: 17647267 Review.
-
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.Med Res Rev. 2005 Jul;25(4):383-97. doi: 10.1002/med.20027. Med Res Rev. 2005. PMID: 15637697 Review.
Cited by
-
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.Int J Mol Med. 2019 Jan;43(1):285-293. doi: 10.3892/ijmm.2018.3963. Epub 2018 Oct 29. Int J Mol Med. 2019. PMID: 30387821 Free PMC article.
-
Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug.Molecules. 2008 Feb 1;13(2):230-54. doi: 10.3390/molecules13020230. Molecules. 2008. PMID: 18305415 Free PMC article. Review.
-
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.Clin Pharmacol. 2016 May 6;8:35-44. doi: 10.2147/CPAA.S94021. eCollection 2016. Clin Pharmacol. 2016. PMID: 27226735 Free PMC article. Review.
-
Valproic Acid Inhibits RhoA-Mediated Vascular Smooth Muscle Cell Contraction.J Korean Med Sci. 2025 Aug 25;40(33):e199. doi: 10.3346/jkms.2025.40.e199. J Korean Med Sci. 2025. PMID: 40856063 Free PMC article.
-
The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights.Int J Mol Sci. 2019 Nov 10;20(22):5615. doi: 10.3390/ijms20225615. Int J Mol Sci. 2019. PMID: 31717614 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical